implicated in CNS protection, we sought to elucidate the protective properties of the reactive astrocytes at the BBB. We have previously shown the importance of the vitamin A metabolite retinoic acid (RA) in embryonic BBB development. Our recent analyses reveal that RA counteracts the deleterious effects of inflammatory cytokines on BBB function, decreases monocyte migration, and induces an immune quiescent phenotype in resting and immune activated brain endothelial cells in vitro. Interestingly, low vitamin A serum levels have been correlated to a worsened disease course in relapsing-remitting MS patients.
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To investigate the role of RA in neuroinflammation, we analysed the RA synthetic pathway in post-mortem MS lesions. We show that reactive astrocytes in MS lesions re-express the enzyme responsible for RA production. Furthermore, increased RA receptor expression indicates active RA signalling in lesions. Using primary human astrocyte cultures, we have reproduced inflammation-induced RA synthesis release in vitro. Assays using human brain endothelium show that RA secretion by reactive astrocytes is an endogenous protective mechanism that reduces functional BBB damage and immune activation during neuroinflammation. Our ongoing research points towards anti-oxidant transcription factor signalling as one of the mechanisms by which astrocyte-derived RA protects the inflamed BBB. Detailed knowledge on the regulation of RA levels in the CNS in astrocytes and its protective effect on the BBB may lead to the development of novel therapies aimed at restoring the BBB and reducing the inflammatory cascade in MS lesions. Central nervous system (CNS) disorders such as ischemic stroke, multiple sclerosis (MS) or Alzheimer's disease are characterized by the loss of blood-brain barrier (BBB) integrity. Here we demonstrate that the small tyrosine kinase inhibitor imatinib enhances BBB integrity in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (MS). Treatment was accompanied by decreased CNS inflammation and demyelination and especially reduced T-cell recruitment. This was supported by downregulation of the chemokine receptor (CCR) 2 in CNS and lymph nodes, and by modulation of the peripheral immune response towards an antiinflammatory phenotype. Interestingly, imatinib ameliorated neuroinflammation, even when the treatment was initiated after the clinical manifestation of the disease. We have furthermore analyzed the transcriptional profile from freshly isolated blood vessels during active and chronic neuroinflammation and identified novel molecular targets involved in BBB integrity and leukocyte transmigration. We have previously shown that imatinib reduces BBB disruption and stroke volume after experimentally induced ischemic stroke by targeting platelet-derived growth factor receptor -α (PDGFR-α) signaling. Here we demonstrate that PDGFR-α signaling is a central regulator of BBB integrity during neuroinflammation and therefore imatinib should be considered as a potentially effective treatment for MS. Background: Leukocyte trafficking at the blood-brain barrier (BBB) is essential for inflammatory responses that clear microbes from the central nervous system (CNS). Leukocytes cross the BBB through a sequence of distinct leukocyte-endothelial interactions, each precisely regulated by an array of molecules. Further, shear forces have a remarkable role herein. Poorly regulated transmigration can be underlain or worsen CNS disorders such as multiple sclerosis (MS) and stroke. Preventing immune cell infiltration in a selective manner therefore holds the promise for effective, safe treatments for patients. Methods: In our in vitro model of the BBB we co-culture brain microvascular endothelial cells with astrocytes on collagencoated filters. Cell lines are of human origin and conditionally immortalized which allows cell growth and differentiation at two distinct temperatures. Peripheral blood mononuclear cells (PBMC) are isolated from healthy donors and perfused across the luminal endothelial surface at flow rates typical of the estimated shear stress in human cerebral capillaries. We also incorporate potent imaging techniques, including Serial BlockFace Scanning Electron Microscopy (3D-EM) and Real-time Multiphoton Microscopy. Results: Enumeration of migrated and attached versus input cells along with manipulation of key molecules confirmed the reliability of our in vitro model. For example, blocking alpha4 integrin on PBMC resulted in reduced numbers of luminallyattached and migrated leukocytes, equivalent to natalizumab treatment in MS. At an ultrastructural level, 3D-EM revealed exciting leukocyte-endothelial as well as unexpected leukocyte-leukocyte interactions in which cells generated filamentous protrusions extending to one another. Further, our newly developed set-up for Multiphoton Imaging enables us to study dynamics of cell trafficking under flow in real time. In our system PBMC undergo rolling, adhesion, crawling and transmigration in discrete steps, as reported from in vivo 2-Photon Imaging. Conclusion: We have developed an in vitro model of the BBB which represents novel technology due to its potential to study cellular interactions under flow in considerable detail. It allows precise experimental control and pharmacological modulation of single effector molecules. Results from this research are likely to promote the development of selective therapeutics that control pathological CNS infiltration of immune cells in neuroinflammatory diseases. 
